Sugi Predict

Sugi Predict / Compounds / SCHEMBL7948775

SCHEMBL7948775

SCHEMBL7948775

CC(C)C1=CCN(Cc2ccccc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 2/20 0.48
▸ MC4R P32245 1/20 0.46
▸ DRD2 P14416 5/20 0.46
▸ HTR1A P08908 2/20 0.46
▸ HTR2A P28223 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ DRD4 P21917 3/20 0.45
▸ DRD3 P35462 3/20 0.45
▸ LMNA P02545 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ TACR1 P25103 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ ACHE P22303 1/20 0.44
▸ APOBEC3A P31941 1/20 0.43
▸ RECQL P46063 1/20 0.43
▸ APOBEC3G Q9HC16 1/20 0.43
▸ HTR6 P50406 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9387302 0.88 SIGMAR1 (0.46) SIGMAR1MC4RDRD2HTR1AHTR2A
SCHEMBL8444407 0.86 TACR1 (0.48) SIGMAR1MC4RDRD2HTR1AHTR2A
SCHEMBL10616944 0.85 APOBEC3A (0.48) SIGMAR1MC4RDRD2HTR1AHTR2A
SCHEMBL19077905 0.83 SIGMAR1 (0.47) SIGMAR1MC4RDRD4LMNAPOLB
SCHEMBL5230745 0.82 KDM4E (0.46) SIGMAR1MC4RDRD2HTR1AHTR2A
SCHEMBL8441289 0.80 KDM4E (0.50) SIGMAR1DRD2HTR1AHTR2AHTT
SCHEMBL10619020 0.79 MEN1 (0.52) DRD2HTR1AHTR2ALMNAMEN1
SCHEMBL1076822 0.78 SIGMAR1 (0.53) SIGMAR1MC4RDRD2HTR1AHTR2A
SCHEMBL1587949 0.78 DRD2 (0.41) DRD2HTR1AHTR2AHTTDRD4
SCHEMBL8831025 0.77 SIGMAR1 (0.44) SIGMAR1MC4RDRD2HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3262036-B1 THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2023-09-13 — — EP disclosed
US-20220153732-A1 PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-05-19 — — US disclosed
EP-3564232-B1 BMP-SIGNAL-INHIBITING COMPOUND RIKEN (JP) 2022-01-26 — — EP disclosed
US-10954216-B2 BMP-signal-inhibiting compound RIKEN (JP) 2021-03-23 — — US disclosed
US-20190337926-A1 BMP-SIGNAL-INHIBITING COMPOUND RIKEN (JP) 2019-11-07 — — US disclosed
EP-3564232-A1 BMP-SIGNAL-INHIBITING COMPOUND Riken (JP) 2019-11-06 — — EP disclosed
US-10308614-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-06-04 — — US disclosed
US-20180086720-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2018-03-29 — — US disclosed
US-20180086720-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2018-03-29 — — US disclosed
US-9073856-B2 Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors ELI LILLY AND COMPANY (US) 2015-07-07 — — US disclosed
US-20140371269-A1 PHENYL METHANESULFONAMIDE DERIVATIVES USEFUL AS MGAT-2 INHIBITORS ELI LILLY AND COMPANY (US) 2014-12-18 — — US disclosed
EP-2807147-A1 PHENYL METHANESULFONAMIDE DERIVATIVES USEFUL AS MGAT - 2 INHIBITORS Eli Lilly and Company (US) 2014-12-03 — — EP disclosed
WO-2013112323-A1 PHENYL METHANESULFONAMIDE DERIVATIVES USEFUL AS MGAT - 2 INHIBITORS ELI LILLY AND COMPANY (US) 2013-08-01 — — WO disclosed
EP-2340021-B1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES HOFFMANN LA ROCHE (CH) 2012-11-07 — — EP disclosed
WO-2010031713-A1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-25 — — WO disclosed
US-20090054460-A1 Piperazine derivatives and methods of use CHEN JIAN J 2009-02-26 — — US disclosed
US-7393852-B2 Piperazine derivatives and methods of use AMGEN INC. (US) 2008-07-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10954216-B2 BMP-signal-inhibiting compound BMP1, BMP2, BMP4 SIGMAR1 4769/4885MC4R 3892/4885DRD2 4415/4885
US-20190337926-A1 BMP-SIGNAL-INHIBITING COMPOUND BMP1, BMP2, BMPR2 SIGMAR1 4808/4885MC4R 3646/4885DRD2 4569/4885
US-20090054460-A1 Piperazine derivatives and methods of use PTGES, PTGES2, PTGIS SIGMAR1 545/4885MC4R 1648/4885DRD2 1569/4885
US-20220153732-A1 PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G SIGMAR1 3889/4885MC4R 3425/4885DRD2 4602/4885
US-10308614-B2 Therapeutic compounds and uses thereof SMARCC1, SMARCC2, SMARCA4 SIGMAR1 1928/4885MC4R 2221/4885DRD2 4216/4885
US-20180086720-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF SMARCC1, SMARCC2, SMARCA4 SIGMAR1 1928/4885MC4R 2221/4885DRD2 4216/4885
US-20140371269-A1 PHENYL METHANESULFONAMIDE DERIVATIVES USEFUL AS MGAT-2 INHIBITORS MGST1, MGAT1, MGAT2 SIGMAR1 2170/4885MC4R 1286/4885DRD2 3501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.